Saltar al contenido principal

ETHNOS_APP

Inicio • Búsqueda • Revistas • Lista 0

Gregory W Mattingly

Datos Biográficos

ID7651275
NOMBREGregory W Mattingly
NOMBRESGregory W
APELLIDOMattingly
FIRMAMATTINGLY G W
AFILIACIONESPolitical Research Associates
ORCID0000-0002-0234-6860
VERIFICADOSí
TOTAL DE OBRAS4
TOTAL DE CITAS0
TOTAL COMO AUTOR4
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2021
AÑO MÁS RECIENTE DE PUBLICACIÓN2023
ÍNDICE H0
  • Serdexmethylphenidate/dexmethylphenidate effects on sleep in children with attention-deficit/hyperactivity disorder

    Open Access•Gregory W Mattingly, Greg W Mattingly et al.•ARTICLE•Frontiers in Psychiatry•2023

    In this analysis of children taking SDX/d-MPH for ADHD, sleep problems did not worsen based on the mean CSHQ total sleep disturbance score. Statistically significant improvements in most CSHQ sleep domains were observed after 1 month and lasted for up to 12 months of treatment

  • Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice

    Open Access•Gregory W Mattingly, Gregory Mattingly et al.•ARTICLE•Frontiers in Psychiatry•2023

    This real-world study demonstrated improvements in functioning, depressive symptoms, and cognitive function in patients with MDD treated with vortioxetine in routine clinical practice in the cohort of patients enrolled in the United States. Outcomes were consistent with the efficacy and safety profile of vortioxetine in randomized controlled trials

  • Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice

    Open Access•Gregory W Mattingly, Hongye Ren et al.•ARTICLE•Frontiers in Psychiatry•2022

    These results demonstrate the effectiveness and tolerability of vortioxetine for the treatment of MDD in a large and heterogeneous patient population representative of that encountered in routine clinical practice

  • The World Federation of ADHD International Consensus Statement

    Open Access•Stephen V Faraone, Tobias Banaschewski et al.•ARTICLE•Neuroscience & Biobehavioral…•2021

    BACKGROUND: Misconceptions about ADHD stigmatize affected people, reduce credibility of providers, and prevent/delay treatment. To challenge misconceptions, we curated findings with strong evidence base. METHODS: We reviewed studies with more than 2000 participants or meta-analyses from five or more studies or 2000 or more participants. We excluded meta-analyses that did not assess publication bias, except for meta-analyses of prevalence. For net…

Sin obras prominentes en esta página.

  • The World Federation of ADHD International Consensus Statement

    Open Access•Stephen V Faraone, Tobias Banaschewski et al.•ARTICLE•Neuroscience & Biobehavioral…•2021

    BACKGROUND: Misconceptions about ADHD stigmatize affected people, reduce credibility of providers, and prevent/delay treatment. To challenge misconceptions, we curated findings with strong evidence base. METHODS: We reviewed studies with more than 2000 participants or meta-analyses from five or more studies or 2000 or more participants. We excluded meta-analyses that did not assess publication bias, except for meta-analyses of prevalence. For net…

  • Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice

    Open Access•Gregory W Mattingly, Hongye Ren et al.•ARTICLE•Frontiers in Psychiatry•2022

    These results demonstrate the effectiveness and tolerability of vortioxetine for the treatment of MDD in a large and heterogeneous patient population representative of that encountered in routine clinical practice

  • Serdexmethylphenidate/dexmethylphenidate effects on sleep in children with attention-deficit/hyperactivity disorder

    Open Access•Gregory W Mattingly, Greg W Mattingly et al.•ARTICLE•Frontiers in Psychiatry•2023

    In this analysis of children taking SDX/d-MPH for ADHD, sleep problems did not worsen based on the mean CSHQ total sleep disturbance score. Statistically significant improvements in most CSHQ sleep domains were observed after 1 month and lasted for up to 12 months of treatment

  • Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice

    Open Access•Gregory W Mattingly, Gregory Mattingly et al.•ARTICLE•Frontiers in Psychiatry•2023

    This real-world study demonstrated improvements in functioning, depressive symptoms, and cognitive function in patients with MDD treated with vortioxetine in routine clinical practice in the cohort of patients enrolled in the United States. Outcomes were consistent with the efficacy and safety profile of vortioxetine in randomized controlled trials

Medicine (4 obras) · Psychiatry (4 obras) · Psychology (3 obras) · Adverse effect (2 obras) · Attention Deficit Hyperactivity Disorder (2 obras) · Depression (economics (2 obras) · Internal Medicine (2 obras) · Major depressive disorder (2 obras) · Treatment of Major Depression (2 obras) · Vortioxetine (2 obras)

Ethnos_APP • Proyecto Open Source • Licencia MIT • Frontend v2.0.0 • Privacidad y Cookies • Documentación de la API: api.ethnos.app/docs • Código de la API: GitHub • DOI: 10.5281/zenodo.17049435 • Código del Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae